Pharmaceutical Drugs Sales Performance Review Report 2021-2023: Focus on United States, Europe, and Japan - ResearchAndMarkets.com
12 May 2023
Vaccine
DUBLIN--(BUSINESS WIRE)--The "A Review of the Best Selling Pharmaceutical Drugs in 2021: 2023 Research Report" report has been added to ResearchAndMarkets.com's offering.
'A Review of the Best Selling Pharmaceutical Drugs in 2021: 2023 Research Report'
This research report incorporates an in-depth analysis of the pharmaceutical drugs market and its competitive landscape through 2021. Major players, competitive intelligence, innovative technologies, and company profiles are discussed in detail.
The report also examines recent developments and product portfolios of major players, and it features market share analysis and rankings in the market. It includes a regulatory landscape analysis that focuses on recent regulations in regions such as the U.S., Europe, and Japan.
Report Includes
An overview of the best-selling pharmaceutical drugs in 2021
Revenue forecast of the top 50 pharmaceutical drugs and assessment of their regulatory landscape
Description of the pharmaceutical drugs applications and information on pharmaceutical drugs patents
Detailed company profiles of the top 50 pharmaceutical drugs
Key Topics Covered:
Chapter 1 Introduction
1.1 Study Goals and Objectives
1.2 Reasons for Doing this Study
1.3 Scope of Report
1.4 Methodology
1.4.1 Primary Data and Information Gathering
1.4.2 Secondary Data and Information Gathering
1.4.3 Market Revenue Forecasts
1.5 Analyst's Credentials
1.6 Custom Research
1.7 Related Research Reports
Chapter 2 Global Pharmaceutical Drug Market
2.1 Overview
2.2 Key Strategies of Major Pharmaceutical Drugs Manufacturers
2.2.1 Distribution Network
2.2.2 Trends
2.2.3 Mergers and Acquisitions
2.2.4 Recommendations
2.3 Key Developments of the Major Pharmaceutical Drugs Manufacturers
2.3.1 Mergers and Acquisitions
2.3.2 Agreements, Joint Ventures, Expansions, Divestments, and Investments
2.3.3 New Product Launches and Approvals
2.4 Long-Term Outlook
Chapter 3 Regulatory Structure: Pharmaceutical Drug Market
3.1 Regulatory Background
3.2 Regulatory Systems for Biopharmaceuticals by Region
3.2.1 U.S.
3.2.2 Europe
3.2.3 Japan
3.3 Regulatory Systems for Pharmaceuticals by Region
3.3.1 U.S.
3.3.2 Japan
3.3.3 India
3.3.4 Brazil
3.4 Regulations for Vaccines
3.4.1 Current Regulatory Issues for Vaccines
3.4.2 Moderna Vaccine Regulation in the U.K.
3.5 Key Regulatory Updates 2021
3.5.1 Pharmaceuticals
3.5.2 Medical Devices
3.6 Code of Federal Regulations (Cfr)
3.7 Good Manufacturing Practice (Gmp) Compliance
3.8 Establishment Registration
3.9 Drug Registration and Listing
3.10 Local Agent Requirements
3.10.1 Responsibilities of the U.S. Agent
Chapter 4 Pricing and Reimbursement: Pharmaceuticals and Biologics
4.1 Pricing and Reimbursement Background
4.2 Pricing and Reimbursement of Pharmaceuticals and Biologics by Region
4.2.1 U.S.
4.2.2 Europe
4.2.3 Japan
4.3 Pricing and Reimbursement Challenges for Pharmaceuticals
4.3.1 Patented Medicines Price
4.3.2 Prices of Older Drugs
Chapter 5 Company Profiles
Abbott
Grifols S.A.Grifols S.A.
A. Menarini Industrie Farmaceutiche Riunite S.R.L.
Merck Kgaa
F. Hoffmann-La Roche Ltd. (Roche)
Ucb S.A.
For more information about this report visit https://www.researchandmarkets.com/r/iy5jel
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Indications
-Targets
-Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.